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Background: Innovative Vision Products, Inc. (IVP)’s scientists developed the lubricant eye 
drops (Can-C™) designed as 1% N-acetylcarnosine (NAC) prodrug of L-carnosine containing 
a mucoadhesive cellulose-based compound combined with corneal absorption promoters in a 
sustained drug delivery system. Only the natural L-isomeric form of NAC raw material was 
speciﬁ  cally synthesized at the cGMP facility and employed for the manufacturing of Can-C™ 
eye drops.
Objective and study design: In the present clinical study the authors assessed vision before 
and after 9 month term of topical ocular administration of NAC lubricant eye drops or placebo 
in 75 symptomatic patients with age-related uncomplicated cataracts in one or both eyes, with 
acuity in one eye of 20/40 or worse (best-corrected distance), and no previous cataract surgery 
in either eye and no other ocular abnormality and 72 noncataract subjects ranged in age from 
54 to 78 years.
Setting: Subjects in these subsample groups have reported complaints of glare and wanted 
to administer eye drops to get quick eye relief and quality of vision for their daily activities 
including driving and computer works. Following 9 months of treatment with NAC lubricant 
eye drops, most patients’ glare scores were improved or returned to normal in disability glare 
tests with Halometer DG. Improvement in disability glare was accompanied with independent 
improvement in acuity. Furthermore, patients with the poorest pretreatment vision were as 
likely to regain certain better visual function after 9 months of treatment with N-acetylcarnosine 
lubricant eye drops as those with the worth pretreatment vision.
Patients or other participants: The authors made a reference to electronic records of the 
product sales to patients who have been made the repurchase of the Can-C™ eye drops since 
December 2001.
Intervention: Based on this analysis of recorded adjustments to inventory, various parameters 
were analyzed during the continued repurchase behavior program, including testimonials from 
buyers. With these ﬁ  gures, researchers judged on the patients’ compliance rate to self-administer 
NAC eye-drops.
Main outcome measure and results: The ophthalmic drug showed potential for the non-
surgical treatment of age-related cataracts for participants after controlling for age, gender and 
daily activities and on a combined basis of repurchases behavior reports in more than 50,000 
various cohort survivors, has been demonstrated to have a high efﬁ  cacy and good tolerability for 
prevention and treatment of visual impairment determined for the older population with relative 
stable pattern of causes for blindness and visual impairment. The mechanisms of prevention 
and reversal of cataracts with NAC ophthalmic drug are considered which include preven-
tion by the intraocular released carnosine of free-radical-induced inactivation of proprietary Clinical Interventions in Aging 2009:4 32
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lens antioxidant enzymes (superoxide dismutase); prevention of 
carbohydrate and metal-catalyzed autooxidation of ascorbic acid-
induced cross-linking glycation reactions to the lens proteins; 
transglycation properties of carnosine, allowing it to compete for 
the glycating agent, protecting proteins (lens crystallins) against 
modiﬁ  cation; universal antioxidant and scavenging activity towards 
lipid hydroperoxides, aldehydes and oxygen radicals; activation 
with L-carnosine ingredient of proteasome activity in the lens; 
chaperone-like disaggregating to lens crystallins activity of NAC 
and of its bioactivated principal carnosine. Blindness incidence 
increased with advancing age, such as cataract and glaucoma, which 
are by far the commonest causes of blindness in our sample and 
in all age groups, glaucomatous neurodegeneration can be treated 
with developed NAC autoinduction prodrug eye drops equipped 
with corneal absorption promoters. The common blinding affections 
presenting in developed countries such as, senile macular degenera-
tion, hereditary chorioretinal dystrophies, diabetic retinopathy are 
poorly represented in our current summary of vital-statistics and 
will be reported inherent in next N-acetylcarnosine ophthalmic 
drug studies.
Conclusion: The authors present evidence, about why only a cer-
tain kind of NAC is safe, and why only certain formulas designed 
by IVP for drug discovery are efﬁ  cacious in the prevention and 
treatment of senile cataract for long-term use. Overall cumulated 
studies demonstrate that the designed by IVP new vision-saving 
drug NAC eye drops help the aging eye to recover by improving its 
clarity, glare sensitivity, color perception and overall vision.
Keywords: age-related ophthalmic diseases, cataract, disability-
glare, halos, Halometer, visual-acuity, N-acetylcarnosine lubricant 
eye drops, repurchase behavior analysis, 50,000-patients’ compli-
ance to self-administer eye drops
Nature, like a Sphinx, 
And the temptation of humans with Her mysteries is stronger 
Considering that maybe there are no mysteries at all.
—F.I. Tyutchev
Introduction
Carnosine (β-alanyl-L-histidine) was discovered and its struc-
ture determined in the very beginning of the 20th century.1 It 
was the ﬁ  rst and the simplest example of biologically active 
peptides (actually a dipeptide), opening the long list of wide-
spread natural protein and peptide regulators of metabolism. 
The biological role of carnosine is illustrated by a clear cor-
relation between its concentration and the functional activ-
ity of muscles, by the period of its accumulation related to 
a speciﬁ  c step of ontogeny, and by the presence of special 
enzymes providing synthesis and metabolic transformation 
of carnosine. Recently we have originally discovered that 
some natural compounds of a peptide character or their 
metal chelates may be among the most potent lipoperoxidase 
mimetics that have ever been characterized.2 L-carnosine 
and its ophthalmic prodrug bioactivating N-acetylcarnosine 
(NAC) are part of this group of products.3 NAC, like its 
parent compound, carnosine, occurs naturally throughout 
the human body. Both compounds are found primarily in 
the heart and skeletal muscles and in the brain. However, 
we have found appreciable levels of L-carnosine in transpar-
ent human lenses which are markedly depleted in mature 
cataracts.4 The concentration of carnosine in transparent 
crystalline lenses detected was about 25 μM. At different 
stages of cataract development, the level of carnosine fell, 
reaching about 5 μM.1 Research with NAC demonstrates 
that it is effective not only in preventing cataracts but also 
in treating them. NAC has been shown to improve vision 
by partially reversing the development of the cataract, thus 
increasing the transmissivity of the lens to light.5
One of the obscure aspects of the carnosine problem 
is the biological signiﬁ  cance of the enzymatic metabolism 
of carnosine or its derivatives in tissues. Thus, in order to 
change an antioxidant status, tissue enzymes can modify 
the NAC molecule and deacetylation will increase in vivo 
the resistance of lens tissues and its cells to oxidative stress. 
This modiﬁ  cation of NAC may serve as a regulator of reac-
tive oxygen species level in the ocular biological tissues 
and ﬂ  uids. The topical administration of NAC as a univer-
sal bioactivating antioxidant for vision in the developed 
and patented lubricant eye drop formulations delivers pure 
L-carnosine and allows its increased intraocular absorption 
into the aqueous humor surrounding the lens, thus enabling 
signiﬁ  cant improvements in anticataract drug efﬁ  cacy and 
the minimization of side-effect from either local or systemic 
drug absorption/bioavailability to the eye, and also creates 
optimization effects in the number of ocular degenerative 
age-dependent disorders.5
The research and development team at Innovative Vision 
Products, Inc. (IVP; County of New Castle, DE USA) 
studied the effects of lubricant eye drops designed as 1% 
NAC prodrug of L-carnosine containing a mucoadhesive 
cellulose-based compound combined with corneal absorption 
promoters in a drug delivery system. The predicted responses 
of the corneal and conjunctival penetrations to the synergistic 
promoters are useful in controlling the extent and pathway of 
the ocular and systemic absorptions of instilled NAC prodrug 
in designed ophthalmic formulations thereof.5 The devel-
oped by IVP NAC prodrug and codrug lubricating eye drop Clinical Interventions in Aging 2009:4 33
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systems (including principal regulatory registered eye drops 
design Clarastill™ and Can-C™ lubricating eye drops) have 
been marketed under numerous brand labels. Several expert 
antiaging companies are supplying the eye health comfort 
NAC drops on the market today with more than 5 years of 
experience and consequently, there exists empirically suc-
cessful reasoning that NAC lubricant eye drops are reputed 
to cure cataracts and other eye diseases.
The risk, cost and social requirement factors drive the 
investigation of pharmaceutical approaches to the manage-
ment of cataracts. More than 17 million people are blind 
because of cataract and 28,000 new cases are reported daily 
worldwide.6 In the United States, over 1.3 million cataract 
operations are performed annually at a cost of $3.5 billion.7 
Forty-three percent of all visits to ophthalmologists by Medi-
care patients are associated with cataract.7 Approximately 
25% of the population over 65 and about 50% over 80 have 
serious loss of vision because of cataract. Since the popula-
tion over 55 is most susceptible to lens opaciﬁ  cation and is 
expected to increase 4-fold worldwide and signiﬁ  cantly in 
the United States,8 cataract is a major disease both in terms 
of numbers of people involved and in economic impact.
The importance of quality of vision (QOV) along with 
quality of life (QOL) in antiaging medicine has been recently 
widely recognized. We have conducted studies to quantita-
tively analyze factors related to QOV using the Halometer 
DG (Disability Glare) tester, a clinically developed ophthal-
mic diagnostic instrument.9 Glare is broadly deﬁ  ned as rep-
resenting those effects of light that impair visual efﬁ  ciency. 
The physical mechanisms and physiological causes of glare in 
human vision are reported.9 These mechanisms are scattering 
in the cornea, lens, and retina, and diffraction in the coher-
ent cell structures on the outer radial areas of the lens. This 
scattering and diffraction are responsible for the “bloom” 
and “ﬂ  are lines” seen around very bright objects. The dif-
fraction effects cause the “lenticular halo”. The quantitative 
assessment of these glare effects was reported by our group, 
and an algorithm for using these clinical characteristics of 
vision to add glare effects to digital lens images in age-
related human cataracts was presented.9–12 Disability glare 
(DG) results when a light source reﬂ  ects from or otherwise 
covers the visual task, like a veil, obscuring the visual tar-
get, reducing its contrast and making the viewer less able to 
see and discriminate what is being viewed. The problem is 
illustrated in Figure 1.
In this paper, the CIE term, DG is used to represent 
retinal exposure from a glare source that results in diffused 
intraocular light scattering within the ocular media. This 
diffused light induces an unwanted optical veil of luminance 
that reduces contrast and target visibility. Currently, there are 
no good instruments for measuring DG, and there is no good 
“metric” for quantifying DG. Despite the fact that several 
tests designed to “penetrate” lens opaciﬁ  cation in order to 
assess visual function at the retinal-neural level are in use 
clinically, each has rather severe limitations, particularly 
in cases where the need for clear deﬁ  nition of functional 
integrity is greatest. For patients with cataract, visual func-
tion in everyday conditions is poorly predicted by classical 
Snellen acuity, grating acuity, and grating contrast sensitivity 
when test measurements are made under “minimal-glare” 
conditions.13 This statement was supported by the Commit-
tee on Ophthalmic Procedures Assessment of the American 
Academy of Ophthalmology on contrast sensitivity and 
glare testing in the evaluation of anterior segment disease.14 
It’s believed that DG assessment should become an inte-
gral part of eye exams for people over 50 years of age. We 
have recently designed an innovative Halometer DG tester 
(Figure 2A–E) that overcomes previous deﬁ  ciencies.9–12 IVP 
patented the original Halometer DG concept and designed 
the vision diagnostic device for commercial implementa-
tion.9–12 The Halometer DG tester is vital for aging drivers 
with poor vision resulting from aging, cataract, and ocular 
disease(s). Glare testing provides secondary informa-
tion concerning cognitive and physical performance. The 
Halometer DG is sensitive even to mild impairments. Such 
information is often ignored or denied until it is advanced 
with marked functional impairment resulting in a serious 
accident. Relationships between computer task performance 
(accuracy and speed) and visual function parameters (visual 
acuity, glare sensitivity, visual ﬁ  eld, and color vision) are 
also important.14 Among this cohort of patients with age-
related cataracts and ocular degenerative disorders, visual 
acuity, disability glare sensitivity, and color vision defects 
are signiﬁ  cant predictors of computer task performance. 
Visual function parameters of the better eye usually plays 
a more signiﬁ  cant role than parameters of the worse eye, 
and disability glare is the signiﬁ  cant predictor of computer 
task accuracy.14 The symptoms include headaches, blurred 
distance vision, halos, double vision, and generally irritated 
and fatigued eyes (Figure 2D–E).
In the present clinical study we assessed vision before 
and after the 9-month term of topical ocular administration 
of NAC lubricant eye drops or placebo in 75 symptomatic 
patients with age-related uncomplicated cataracts in one 
or both eyes, with acuity in one eye of 20/40 or worse 
(best-corrected distance), and no previous cataract surgery Clinical Interventions in Aging 2009:4 34
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Bright luminaire or skylight
Angle of incidence: I
Angle of reflectance: R
     I = R
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      visual task
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Disability Glare
Figure 1 Disability glare results when a light source reﬂ  ects from or otherwise covers the visual task, like a veil, obscuring the visual target, reducing its contrast and making 
the viewer less able to see and discriminate what is being viewed. A. This drawing illustrates the problem. In this example, bright light from a ceiling/window light ﬁ  xture or 
skylight is reﬂ  ected from the visual task surface, and into the observer’s eyes, veiling his recognition of the target visual content. Nearly as much light is reﬂ  ected from the 
white paper as from the black ink making the letters, so that the contrast is low and the text is washed out and difﬁ  cult to read. Such glare “disables” the process of reading. 
B. The example of outdoor glare.
B
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in either eye and no other ocular abnormality and 72 
noncataract subjects ranged in age from 54 to 78 years. Sub-
jects in these subsample groups have reported complaints of 
glare and wanted to administer eye drops to get quick eye 
relief and quality of vision. Glare sensitivity was measured 
with the Halometer DG tester. Prior to treatment with NAC 
lubricant eye drops there was signiﬁ  cant disability glare 
that was not correlated with acuity. The disability glare 
was especially manifested under nighttime conditions and 
expressed during a prolong work with a computer-controlled 
video display.
Following 9 months of treatment with NAC lubricant eye 
drops (Can-C™) (Figure 3, Table 1), most patients’ glare 
scores were improved or returned to normal in disability 
glare tests with Halometer DG. Improvement in disability glare 
was accompanied with independent improvement in acuity 
(Table 5). Furthermore, patients with the poorest pretreatment 
vision were as likely to regain certain better visual function 
after 9 months of treatment with NAC lubricant eye drops as 
those with the better pretreatment vision.
NAC prodrug and codrug ophthalmic formulations are 
applied topically to the eye and moreover, its controlled 
Figure 2A Halometer DG (face and rear) projection 1, device base; 2, support bar; 3, feed source; 4, block unit for glare testing as seen by subject; 5, rheostat to regulate 
source brightness; 6, button to turn on/off the voltage feed; 7, clamp; 8, glare source window; 9, moveable optotypes (target); 10, mechanical mechanism for moving the 
optotypes to/from the glare source; 11, voltage feed plug; 12, a button for choosing among different optotypes, operator side; 13, electronic display of shifted optotype posi-
tion, operator side; 14, metric scale of optotype distance from glare source, operator side; 15, metric distance scale of the optotype distance from glare source, operator 
side. B. Principle of the disability glare test, based on the measurement of the glare radius (r, mm) a new metric for glare sensitivity. I0 = Indicatrix of light scatter; ϕ = angle. 
The technique utilizes a self-illuminating red or green optotype target and tangential 2 mm ‘point light source’ seen from a distance of 30 cm. The patient’s task is to 
move the optotype closer to the glare source until it disappears due to the veiling glare from the glare source. A halometer score is determined as follows. The illuminous 
(in red or green) target is approached from the source so that the patient becomes unable to distinguish the target from the source and then, the target is slowly taken 
away until the exact moment when the patient distinguishes the target; at this time, the incident light angle ϕ between the source and the target is measured. The target 
is always ﬁ  xated with the foveal vision. The target and the ‘point light source’ are viewed in the same vertical plane, tangential to the plane of emitted light. In this case, to 
measure the angle ϕ of the incident light between the source and the target, it is necessary only to measure its projection on this vertical plane, which means to measure 
the distance between the source and the target. The measured glare radius is deﬁ  ned as a target image projection for the vector of light scatter (indicator of light scatter 
I = I0cos2 ϕ) when the glare source is activated and the patient is asked to recognize the target during illumination of the eye with a glare source. C. Photograph of working 
prototype of the Halometer DG tester. Halometer DG instrument can provide the valuable data on the intraocular light scatter in cataracts. The instrument can be used 
in the pre-testing examination room of optometrist and ophthalmologists ofﬁ  ces, at Department of Motor Vehicle licensure facilities or incorporated within automobiles, 
for self testing. D. Vision problems during computer use. The eyes ﬁ  nd it difﬁ  cult to focus on the pixel characters. They can focus on the plane of the computer screen, but 
cannot sustain that focus. The eyes focus on the screen and relax to a point behind the screen, which is called the resting point of accommodation (RPA) or dark focus. The 
RPA is different for every individual, but for almost everyone, it is further away than the working distance to the computer. The working distance is the distance from the 
computer user’s eyes to the front of the screen. Therefore the eyes are constantly relaxing to the RPA, and then straining to refocus on the screen. This constant ﬂ  exing 
of the focusing (ciliary body) muscles is what creates fatigue, and generates burning and tired eyes. In clinical studies, it has been found that there is a signiﬁ  cant difference 
in the glasses prescription required for focusing on a standard printed near card (called a Snellen card) and focusing on the image of a typical computer screen, both at a 
viewing distance of 20 inches. Many patients needed a different correction in each eye. E. As light passes through the cataractous lens, it is diffused or scattered. The result 
is blurred or defocused vision.Clinical Interventions in Aging 2009:4 37
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Figure 3 Can-C™ N-acetylcarnosine lubricant eye drops developed, manufactured 
at the cGMP manufacturing facility and worldwide patented by Innovative Vision 
Products, Inc, Formulation.21–23 The composition is in the form of isotonic solution. 
Because the composition is applied to the eye, the composition is sterile. The isotonicity 
of ophthalmic preparation was measured and adjusted as calculated correctly by 
addition of small concentrations of sodium chloride. The speciﬁ  cation of the unique 
nonracemized natural (L)-isomer form of N-acetylcarnosine (see 3D structural formula) 
recipient included in the Can-C™ is presented in Table 1.
Table 1 Speciﬁ  cation of cGMP manufactured N-acetyl-L-carnosine 
used in IVP drug Can-C™ development and clinical studies
No Test name Speciﬁ  cation
1 Appearance White powder
2 Identiﬁ  cation Positive
3 Optical rotation [α]20
D +25.2º− +27.5º
4 pH 4.5–5.5
5 Heavy metals NMT 10 ppm
6 Related substances L-carnosine: NMT 0.3%
Others: NMT 0.2%
7 Residual solvent 2-propanol: NMT 500 ppm
8 Water NMT 5.0%
9 Residue on ignition NMT 0.10%
10 Assay NLT 99.5% (HPLC area)
Abbreviations: NMT, not more than; NLT, not less than.
time-released ophthalmic ingredient, L-carnosine, exerts 
antiglycation, bioactivating antioxidant properties in the 
lens and cornea as a scavenger of lipid peroxides, singlet 
oxygen, and OH⋅radicals and spatial aspects of intracellular 
pH regulation.5,15 In contrast to the possible pirated brands 
of NAC eye drops available on the market that employ 
D/L-isomeric forms of NAC, in the IVP conducted clini-
cal studies only the natural L- isomeric form of NAC raw 
material was speciﬁ  cally synthesized at the cGMP facility 
and employed for the manufacturing of the Can-C™ eye 
drops.
In the initial stages and the planning of the present study, 
the enrolled patients suffered from different degrees of glare 
problems. The purpose of this study is to examine the effects 
of a most often recommended short-term 9-month treatment 
with 1% NAC in ophthalmic formulation with a lubricant, 
carboxymethylcellulose, on improvement of visual impair-
ment and glare disability in older adult subjects and older 
patients with cataract whose occupations frequently involve 
driving or computer activities.
Strengths of this study design are the use of a comparison 
group of patients with cataract and older subjects (including 
drivers or computer users) who were treated with placebo 
(Control group) followed prospectively over the same time 
period and the statistical adjustment for potential differences 
in the treated with NAC groups that could serve as the indica-
tion for the hypothesized improvement effect on vision for 
better occupation returns. We used a randomized design that 
was ethical since NAC is an accepted and proven therapeutic 
modality of vision care available on the market of antiaging 
medicine since 2002.10,15–18
What we have found is there is currently a signiﬁ  cant 
rise in the purchase orders that request a vendor/supplier to 
furnish the Can-C™ eye drops. We have ﬁ  rst made a refer-
ence to electronic records of the product sales to patients who 
have been made the repurchase of the Can-C™ eye drops 
since December 2001. Based on this analysis, we record 
adjustments to inventory, making record sale during the 
continued repurchase program and analyze simultaneously 
the various parameters, including testimonials. With these 
ﬁ  gures, researchers judged on the patients’ compliance rate 
to self-administer eye-drops.
Materials and methods
The ﬁ  rst enrolled cohort of examined subjects consisted 
of  75 older adults with age-related uncomplicated cataracts 
in one or both eyes, and 72 adult subjects who did not 
have cataract in either eye. Patients in these subsamples 
suffered from different degrees of glare problems. Those 
with cataract ranged in age from 53 years to 83 years 
(mean ± SD, 69 ± 8 years), with 48% female, 100% white 
and of non-Hispanic origin. The noncataract subjects 
ranged in age from 54 to 78 years (mean ± SD, 66 ± 8 years); 
53% were female, with 100% being white. Subjects who 
were cataract free had to meet the same inclusion criteria 
as the subjects with cataract described previously.9,10,16–18 
All subjects with cataract were required to meet the follow-
ing inclusion criteria: (1) cataract in one or both eyes with 
best-corrected visual acuity of 20/40 or worse in one or Clinical Interventions in Aging 2009:4 38
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both eyes as indicated by the medical record; (2) no previ-
ous cataract surgery in either eye; (3) a primary diagnosis 
of cataract in the medical record; (4) living independently 
in the community; specific items were needed to be 
addressed if appropriate; (5) driving skills: legally licensed 
to drive and drove during the 5 years prior to enrollment; 
(6) related general or eye health problems experienced 
during computer use: this was assessed by asking subjects 
if they have any symptom problems in the speciﬁ  c areas 
listed in Table 2, Figure 2D. Among participants, bilateral 
cataracts were present in 95% of subjects according to 
the medical record from the most recent eye examination 
(within 1 month of enrolment). In the right eye, 46% had 
nuclear sclerotic cataract, 8% had cortical cataract, 9% had 
posterior subcapsular cataract, and 38% had a combination 
of at least two types. The breakdown was similar in the left 
eye, with 49% nuclear sclerotic, 10% cortical, 7% posterior 
subcapsular, and 35% combination. Seventy-four percent of 
subjects with cataract had no additional ocular conditions 
other than refractive error; 6% had early nonexudative age-
related maculopathy, 9% had primary open-angle glaucoma 
(POAG) associated with cataract, 3% had diabetic reti-
nopathy, 1% had a combination of two of these problems, 
and 7% had another ocular condition. Subjects who were 
cataract-free had to meet the same inclusion criteria as the 
subjects with cataract, except that they were required to be 
Table 2 Computer user questionnaire Do you notice any of these 
visual symptoms? Please rate the following symptoms by underlining 
the appropriate description
Symptom Severity
Headaches during or after working 
at the computer
Mild Moderate Severe
Overall bodily fatigue or tiredness Mild Moderate Severe
Burning eyes Mild Moderate Severe
Distance vision is blurry when 
looking up from the computer
Mild Moderate Severe
Dry, tired, or sore eyes Mild Moderate Severe
Squinting helps when looking 
at the computer
Mild Moderate Severe
Neck, shoulder, or back pain Mild Moderate Severe
Double vision Mild Moderate Severe
Letters on the screen run together Mild Moderate Severe
Driving/night vision is worse after 
computer use
Mild Moderate Severe
“Halos” appear around objects 
on the screen
Mild Moderate Severe
Need to interrupt work 
frequently to rest eyes
Mild Moderate Severe
free of cataract and to have a best-corrected visual acuity of 
20/25 in each eye, according to medical record review. No 
cataract-free subjects had secondary eye conditions other 
than refractive error.
Patients with known or presumed hypersensitivity to 
any component of the ophthalmic preparations (active 
substances or excipients), and those treated with drugs that 
could interfere with this trial, were also excluded from the 
study. The subjects were recruited and examined by IVP 
ophthalmology practices. The study protocol was approved 
by the corporative review board for human use. After the 
purpose of the study had been explained, each subject 
was asked to sign a document of informed consent before 
enrolling. Demographic data, driving status during the 
prior 5 years and computer use at work were conﬁ  rmed by 
interview (Table 3).
Procedures
After enrolment, subjects were computer-randomized into 
two groups assigned according to the double blind method: 
to receive treatment with NAC 1% eye drops (Can-C™), 
or to a control group who received placebo eye drops. The 
blinded testing was carried out by an independent medical 
worker who handed out the NAC versus placebo eye drops 
(control group) to the randomized subject members of the 
clinical groups. The enrolled subjects underwent follow-up 
examinations at baseline and after 9 months of enrolment. 
Test examiners were masked to the driving histories of all 
subjects. Two types of visual functions were assessed: visual 
acuity and glare sensitivity (DG). All acuity measurements 
were made while subjects wore the lens correction they 
typically used during the performance of everyday distance 
activities, including driving. Each eye was assessed sepa-
rately. Distance acuity was measured as described before 
using the letter chart and its standard protocol, and was 
expressed as log minimum angle resolvable.9,10,16–20 For each 
eye, visual acuity measurements were grouped into four 
categories: 20/25 or better, 20/25–20/30, 20/35–20/50, and 
worse than 20/50. These cut-off points were chosen because 
they were the approximate quartiles of the acuity distribu-
tion and included the practically signiﬁ  cant cut-off point 
for driving licensure in many countries (20/40 to 20/50). 
Some of the vision problems from this course will include 
computer-related work and the circumstances under which 
that work is performed.
Slit-lamp biomicroscopic examination or exampled pho-
tographic registration was performed after pupil dilation to 
a minimum of 6 mm with tropicamide.Clinical Interventions in Aging 2009:4 39
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Table 3 Demographic and ergonomic occupational characteristics 
of cataract and no cataract adult subjects enrolled in the study
Cataract No cataract
 n% n%
Total 75 72
Age groups
50–59 years 18 24 18 25
60–69 years 43 57 40 56
70–85 years 14 19 14 19
Sex
Female 36 48 38 53
Male 39 52 34 48
Race White 75 100 White 72 100
Driving exposure*
Total 40 53 42 58
150 km/wk 23 58 17 41
= 150 km/wk 17 42 25 59
Computer users
Total 47 63 51 71
Occasional computer users** 17 36 21 41
Moderate computer users** 18 38 16 31
Intensive computer users** 12 26 14 28
Notes: Data are presented as numbers and percentages. *Driving subjects were 
classiﬁ  ed into 2 categories according to whether they drove more or less than the 
median number of km (150 km) driven per week based on the distribution of all 
subjects. Although this was a self-report measure, prior studies indicate that older 
adults can provide valid estimates of driving exposure [18, 24]. **Occasional computer 
user: This individual typically uses the computer for less than 3 hours per day. This 
user tends to have an extensive variety of different tasks (computer and other) and 
they are unlikely to regularly spend extended amounts of time sitting and working 
at the computer. **Moderate computer user: This individual typically uses the com-
puter between 3–5 hours per day. This user tends to have some variety in the daily 
work tasks but they regularly may spend up to half the workday at the computer. 
**Intensive computer user: This individual typically spends more than 5 hours per 
day on the computer. This user may have a limited number of noncomputer-related 
tasks or none at all. These individuals are considered to be at high risk of developing 
computer-related injuries if precautions such as appropriate workstation design, layout 
and work practices are not addressed.
DG was deﬁ  ned with an optical instrument and method 
for measuring susceptibility to glare of a human vision 
system as described9–12,16–18 and schematically presented in 
Figures 2A–C. A constant “point”-like bright glare source is 
used to create the glare condition (Figure 2C). The examining 
room was dark (less than 20 foot-candles) as typical when 
working with the glare testers to assure maximum contrast 
of the projected target. Tests were performed with the best 
correction in place. The indicator of optotypes on the front 
or back panels of the instrument indicated the tested optotype 
to the patient or clinician, respectively. The diagnostic block 
of a device contained source light window (glare source) 
and the moving indicator of the optotypes illuminated with 
red or green light (Figure 2A, C). The back panel of the 
Halometer device facing the clinician was equipped with 
a chart/scale and with a moving indicator of the optotype 
transition. According to a special embodiment of the inven-
tion,9–12,16–18 for the clinical testing of glare sensitivity of a 
patient we used an illuminated target with red or green color, 
which enables the assessment of the effect of wavelength on 
the scattered light.
Treatments with NAC 1% lubricant 
eye drops
NAC eye drops (Can-C™) contained a 1% solution of 
NAC21–23 with a lubricant, 0.3% carboxymethylcellulose, in 
the isotonic ophthalmic formulation in borate buffer with 
preservative benzyl alcohol (corneal absorption promoter) 
and showed the increased intraocular absorption of the active 
principle (L-carnosine) in the aqueous humor compared to 
topical administration of a pure 1% NAC solution: 
Deionized water  970 g
Glycerine, 1.0%  13 g
N-Acetylcarnosine, 1.0%  10 g
Carboxymethylcellulose, 0.3%  3 g
Benzyl alcohol, 0.3%  3 g
Potassium borate  7.91 g*
Potassium bicarbonate  3.47 g*
The ophthalmic formulation thus creates a facility to 
examine the efﬁ  cacy of treatment for improvements of vision 
during the short-term periods of administration of NAC 1% 
eye drops (9 months in the present study).The administration 
schedule was two drops instilled twice daily, for patients 
assigned to NAC and those assigned to placebo (the same 
formulation without NAC, 1%) alone for 9 months. The use 
of other topical or nutritional antioxidants was not measured 
or evaluated between the two groups. The control groups 
and the treated group did not take any prescribed antioxidant 
vitamins that might have added to the antioxidant level. 
Neither the investigators nor the patients knew who was 
receiving NAC.
Statistical analyses
Statistical analysis was performed by Student’s t test; 
p = 0.05 was taken as the upper limit of signiﬁ  cance. To 
assess associations, correlation and linear regression analyses 
were used.
*Or what is necessary to bring the solution up to a pH of ∼6.3–6.8.Clinical Interventions in Aging 2009:4 40
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Repurchase earnings analysis
The major factors that led to the sharp increase in net earnings 
for the quarters of 2007 compared to the corresponding quar-
ters of 2003 were a signiﬁ  cant increase in selling, general 
and administrative expenses for the promotion of Can-C™ 
NAC lubricant eye drops to public. The launch of Can-C™ 
ophthalmic formulation and continuing strong sales as the 
anticataract and antiglare product contributed most of the sales 
growth in the USA and Europe. The Computer-Based Facilities 
Inventory and Utilization Management Information Subsystem 
allowed authors to analyze the trades that occurred and ongoing 
from the fourth quarter of 2002 till the third quarter of 2007 
and now they have in place a publicly-announced repurchase 
program that, after calculation of the number of sold eye drops, 
generally supports the enhanced patient’s compliance and 
improved safety of the drug candidate in subjects who may self-
administer the prescribed by IVP medication (NAC lubricant 
eye drops) for the reduction or treatment of cataracts, and every 
challenge opportunity is taken to promote self-care.
Patient compliance in both groups described in this study 
to self-administer NAC lubricant eye drops (Can-C™) was 
considered excellent.
Results
Sample characteristics
Table 3 lists the demographic and ergonomic occupational 
characteristics of the cataract (n = 75) and noncataract groups 
(n = 72). Those with cataract were similarly older on average 
with the noncataract group of subjects. Both groups were split 
evenly between males and females, and had similar racial 
composition in a totally white population.
Table 4 lists the visual function for both groups enrolled in 
the study and the distribution of visual acuity and disability glare 
scores for subjects with cataract and those without. As would be 
expected by the case deﬁ  nition for cataract group membership, 
those in the cataract group had impairments in visual function 
as compared to the no-cataract group. This was true for both the 
“worse” and better” eyes. In addition, visual acuity in the range 
of 20/35 to 20/50 and disability glare readings in the range of 
glare radius more than 12 mm was associated with driving difﬁ  -
culties (such as crash involvement) and computer-related injuries 
(Table 2). Although not statistically signiﬁ  cant, there was also a 
possible relationship between visual acuity worse than 20/50 and 
crashing during driving experience.24 DG (glare radius measured 
in millimeters) was correlated for statistical signiﬁ  cance with 
visual acuity at red and green targets at baseline and 9-month 
examination interval in the total samples of older subjects with 
cataract and noncataract older adult subjects (Table 5).
Older subjects enrolled in the study were divided into two 
groups: treated with NAC and control group (Tables 6 and 7). 
Table 6 lists the analogous and adjusted analyses for the 
worse eye, which generated results in the eyes with cataract 
upon treatment with NAC prodrug ophthalmic formulation 
are qualitatively similar to those for the better eye. None of 
the baseline differences between the different groups was 
signiﬁ  cant. The two groups were similar in smoking history, 
sunlight exposure, and alcohol use. There was no substantial 
Table 4 Distribution of visual acuity and disability glare in the 
cataract and noncataract groups of the adult subjects enrolled in 
the study at baseline examination
Adult subjects
Cataract
group
Noncataract 
group
n%n%
Total 75 72
Worse eye
Visual acuity
20/25 or better 9 12 50 70
20/25 to 20/30 14 19 13 18
20/35 to 20/50 48 64 6 8
Worse than 20/50 4 5 3 4
Disability glare readings 
(glare radius)
At red target
12 mm 10 14 27 38
12 mm 65 86 45 62
At green target
12 mm 7 9 20 28
12 mm 68 91 52 72
Better eye
Visual acuity
20/25 or better 12 16 53 74
20/25 to 20/30 30 40 9 12
20/35 to 20/50 25 34 7 10
Worse than 20/50 8 10 3 4
Disability glare readings 
(glare radius)
At red target
12 mm 29 38 40 55
12 mm 46 62 32 45
At green target
12 mm 18 24 24 34
12 mm 57 76 48 66
Notes: Normal measures of glare sensitivity of young subjects (20–30 years) with 
best correction without cataracts are 3 ± 2 mm (mean SD) of at least four measure-
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difference in the use of sunglasses, where the patients lived, 
or occupational hazard exposure between the two groups.
Ophthalmic examinations indicated that the methodologi-
cal variances of measurements were approximately equal. 
Correlations of glare sensitivity at red versus green targets 
were signiﬁ  cant (Table 5). Intraoperator correlation coefﬁ  -
cients obtained as repeated measurements for each combina-
tion of operator, eye (right or left), and glare radius (at red 
and green targets) were statistically signiﬁ  cant and presented 
earlier.9,10,16–18 Overall, the reproducibility for the one operator 
was good. Tables 4–8 summarize the effects of study treatment 
on visual acuity and glare sensitivity over 9 months in older 
subjects with cataract and no cataract. In the control placebo-
treated group, comparison with baseline values showed some 
variability of data in gradual worsening of glare sensitivity at 
red and green targets and minimal visual acuity changes over 9 
months (Table 7). Glare sensitivity indicated mostly changes in 
lens clarity and conﬁ  rmed the tiny changes in the optical media 
of the eye at the short-term follow up examinations when slit 
lamp associated image analysis data and densitometric read-
ings did not differ signiﬁ  cantly with baseline.9,10,16–18
In the NAC-treated group, 9-month follow-up generally 
showed an improvement in visual acuity (according to the 
distribution score of distance acuities in worse and better 
eyes ) and a signiﬁ  cant improvement in glare sensitivity at 
red and green targets was documented in worse and better 
eyes using a critical cut point halometer score (Tables 6, 8). 
Visual acuity was mostly improved in older subjects with 
cataract in a worse and better eyes and an improvement in 
glare sensitivity was found both in older subjects with cata-
ract and noncataract older adult subjects in worth and better 
eyes after 9 months of treatment with NAC. The exampled 
images of cataract reversal in older subjects are presented on 
the slit lamp images just for note (see Figure 4).
The NAC-treated eyes had statistically signiﬁ  cant differ-
ence in VA, glare sensitivity compared with the control group 
(p  0.001) at 9-month time point of treatment, as supported by 
the overall t-test results of the ratio of the follow-up data to the 
baseline values (Table 8). The previously published data illustrate 
examinations over 24 months of the eyes that were treated with 
NAC to show that the effect of treatment is sustainable over more 
prolonged periods.10,16–18 In the eyes of older subjects with dif-
ferent localization and grade of cataract and in noncataract older 
adult subjects, short-term and prolonged treatment with NAC did 
not seem to result in a worsening of the visual outcome in this 
study and elsewhere.10,16–18 Topical short- or long-term admin-
istration of 1% NAC to the eye was very well tolerated, with no 
ocular or systemic adverse effects, no hyperemia of conjunctival 
vessels, and no signs of allergy or other toxic manifestations 
being reported. No clinically signiﬁ  cant changes from baseline, 
and no statistically signiﬁ  cant differences between the treatment 
and control groups, were observed regarding ocular comfort and 
Table 5 Linear correlation coefﬁ  cients (R) between the characteristics of older subjects with cataract and noncataract older adult 
subjects measured by visual acuities (VA) and glare radius (GR at red and green targets) at baseline and at 9-month follow-up ophthalmic 
examinations
Baseline study 9 months
Parameter VA GR red target GR green target VA GR red target  GR green target
Older subjects with cataract+
VA X −0.63* −0.65*  X −0.47 −0.45
GR red target X +0.83* X +0.94*
GR green target X X
Older adult no-cataract subjects++
VA X −0.61* −0.66* X −0.43 −0.46
GR red target X +0.81* X +0.91* 
GR green target X X
Notes: +Number of eyes examined 75; *p  0.01; ++Number of eyes examined 72.
Figure 4 The pictures show the treatment of human cataract in the older subject 
with the eye drops of 1% Can-C™ for the period of 5 months. The left image shows 
the appearance of cataract which resembles a bat in its form and the right image 
shows that this opacity has disappeared after the cited period after treatment with 
n-acetylcarnosine is completed. The lens has become clearer.Clinical Interventions in Aging 2009:4 42
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Table 6  Visual function in the better and worse eyes after 9 months 
of treatment with N-acetylcarnosine 1% eye drops (Can-C™) 
versus baseline examination
Adult subjects
Cataract
group 
Noncataract 
group
 n% n%
Total 39 37
Baseline examination
Worse eye
Visual acuity
20/25 or better  5 13 26 70
20/25–20/30 8 21 5 14
20/35–20/50 22 56 3 8
Worse than 20/50 4 10 3 8
Disability glare readings 
(glare radius)
At red target
12 mm  61 5 1 5 4 1
12 mm 33 85 22 59
At green target
 12 mm 4 10 11 30 
12 mm 35 90 26 70
Better eye
Visual acuity
20/25 or better 5 13 25 68
20/25–20/30 12 31 8 22
20/35–20/50 17 43 2 5
Worse than 20/50 5 13 2 5
Disability glare readings 
(glare radius)
At red target
12 mm 10 26 21 57
12 mm 29 74 16 43
At green target
12 mm 82 1 1 2 3 2
12 mm 31 79 25 68
After 9 months of treatment 
with N-acetylcarnosine 1% eye drops
Worse eye
Visual acuity
20/25 or better 9 23 27  73
20/25–20/30 16 41 7 19
20/35–20/50 13 33 2 5
Worse than 20/50  1 3 1 3
Disability glare readings (glare radius)
At red target
12 mm  12 30 25 67
12 mm 27 70 12 33
(Continued)
Table 6 (Continued)
Adult subjects
Cataract
group 
Noncataract 
group
 n% n%
At green target
12 mm 10 25 21 56
12 mm 29 75 16 44
Better eye
Visual acuity
20/25 or better 15 38 30 80
20/25–20/30 18 47 5 14
20/35–20/50 4 10 1 3
Worse than 20/50 2 5 1 3
Disability glare readings 
(glare radius)
At red target
12 mm 18 45 30 81
12 mm 21 55   7 19
At green target
12 mm 19 46 21 57
12 mm 21 54 16 43
ocular signs and symptoms (lack of burning and stinging, blurred 
vision, ocular dryness, superﬁ  cial punctate keratitis, foreign body 
sensation, itching, ocular discharge, ocular pain, tearing, ocular 
inﬂ  ammation, photophobia). All patients completed the study 
without any problems related to their allocated treatment.
The board of directors analyzed the repurchase behavior of 
Can-C™ in open market programs. The product has been on 
the market since November, 2001 and it is well known accord-
ing to the records how many boxes of Can-C™ are actually 
repurchased. The analyses in this paper demonstrate the 
repurchase behavior of patients in more than 50,000 individual 
buyback programs. We ﬁ  nd that repurchase announcements 
during 5 recent years of follow-up give the credible ﬁ  gure 
of 50,000 patients who are compliant users of Can-C™ eye 
drops for published therapeutic indications (including treat-
ment of cataracts) and demonstrate the safety of all-in-one eye 
drops on a daily basis. On average, these patients repurchase 
more boxes of the drug than they originally authorized over 
the last four quarters following the announcement of greater 
sales, though there is considerable variation across patients’ 
requests. We examine the factors inﬂ  uencing repurchase 
behavior, and ﬁ  nd that repurchases in the latest quarters are 
associated with a number of variables, including the efﬁ  cacy 
of the product and its persistent safety to control the signs of Clinical Interventions in Aging 2009:4 43
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Table 7   Visual function in the better and worse eyes after 
9 months of treatment with placebo (Control group) versus 
baseline examination
Adult subjects
Cataract
group
Noncataract
group
n% n%
Total 36 35
Baseline examination
Worse eye
Visual acuity
20/25 or better 3 8 21 60
20/25–20/30 7 19 7 20
20/35–20/50 23 64 5 14
Worse than 20/50 3 8 2 6
Disability glare readings (glare radius)
At red target
12 mm 92 5 1 7 4 9
12 mm 27 75 18 51
At green target
12 mm 61 7 1 1 3 1
12 mm 30 83 24 69
Better eye
Visual acuity
20/25 or better 11 31 25 72
20/25–20/30 17 47 5 14
20/35–20/50 6 17 5 14
Worse than 20/50 2 5 0 0
Disability glare readings (glare radius)
At red target
12 mm 19 53 23 66
12 mm 17 47 12 34
At green target
12 mm 13 36 16 46
12 mm 23 64 19 54
After 9 months of treatment with placebo
Worse eye
Visual acuity
20/25 or better 2 6 19 54
20/25–20/30 6 17 9 26
20/35–20/50 25 69 5 14
Worse than 20/50 3 8 2 6
Disability glare readings (glare radius)
At red target
12 mm 82 2 1 6 4 6
12 mm 28 78 19 54
At green target
12 mm 51 4 82 3
12 mm 31 86 27 77
(Continued)
Table 7 (Continued)
Adult subjects
Cataract 
group
Noncataract 
group
n% n%
Better eye
Visual acuity
20/25 or better 9 25 25 71
20/25–20/30 17 47 5 14
20/35–20/50 8 22 5 14
Worse than 20/50 2 6 0 0
Disability glare readings 
(glare radius)
At red target
12 mm 16 44 21 60
12 mm 20 56 14 40
At green target
12 mm 10 28 14 40
12 mm 26 72 21 79
glare sensitivity, cataract amelioration, and quality of vision 
during daily life activities. We also consider the past and cur-
rent returns, proﬁ  tability, and prior repurchase activity.
According to the records of repurchase behavior, the 
unique and patented NAC lubricant all-in-one eye drops 
formula Can-C™ can also provide beneﬁ  cial results with 
the following eye-disorders:
• Presbyopia.15,23
•  Open-angle primary glaucoma (in combination with 
beta-blockers).
• Corneal  disorders.
•  Computer vision syndrome.
• Eyestrain.
• Ocular  inﬂ  ammation.
• Blurred  vision.
•  Dry eye syndrome.
• Retinal  diseases.
•  Vitreous opacities and lesions.
•  Complications of diabetes mellitus and other systemic 
diseases.
•  Contact lens difﬁ  culties, particularly with soft contact 
lenses. (Not only do the lubricants in the Can-C™ NAC 
eye-drop help to make contact lenses more comfortable, 
but NAC is also believed to reduce the build up of lactic 
acid in the eye, thus enabling the lens to be left safely in 
the eye for longer).Clinical Interventions in Aging 2009:4 44
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We also investigate how sales outstanding change 
following repurchase program announcements. Over the 
test last year period the average increase in sales is about 
80% and only about 35% of the number is repurchased. For 
the most part, changes in sales of Can-C™ are inﬂ  uenced by 
the same factors affecting repurchases and in the predicted 
direction of warranted efﬁ  cacy and safety of the product. 
Table 9 is presenting the exampled but most typical and 
standard testimonials received from patients who have pur-
chased originally Can-C™. The NAC lubricant eye drops 
have been successfully used for medically oriented home 
health care usually helping seniors recover or exercise with 
aid in recovery from visual impairment or illness including 
cataracts (Figure 5). Medically oriented home-health care 
represents less than half of formal home-health services 
rendered to the long-term-care population. It is important to 
note that most work for home health agencies, hospitals, or 
public health departments are licensed by the state.
Discussion
It is foreseen that the health problems of the elderly are 
multiplying exponentially with the demographic changes in 
our aging population. Visual impairment represents one of 
the most signiﬁ  cant of these problems, not only in terms of 
eye diseases, but because of the associated dangers affecting 
the rest of the body.25
The four most prevalent age-related ocular diseases are 
macular degeneration, open-angle glaucoma, cataract, and 
diabetic retinopathy.26,27 Normal visual changes that occur 
with aging include presbyopia, decreased contrast sensitivity, 
decreased dark/light adaptation, and delayed glare recovery.28 
This decline in vision is associated in part with an increase 
in vehicular accidents per mile driven by the elderly.29 The 
visually demanding computer task had a more pronounced 
effect on the elderly than on the young. In this study, we 
examined the visual function and glare disability of older 
subjects without cataract and in the presence of cataract as 
a patients’ perception of their daily living ability to perform 
vision dependent tasks. The traditional clinical measurement 
of vision, Snellen letter visual acuity, can provide an inade-
quate measure of forward light scatter relevant to glare effects 
in adult subjects.30,31 To determine whether glare sensitivity 
(halos) was signiﬁ  cantly responsible for the change in visual 
functions in older subjects with cataract, we proposed a new 
halometer process, which is a form of disability glare test. In 
a previous study,9 we indicated that a set of halometric exami-
nation data at red and green targets would indicate that the 
condition of optical changes (improvement or deterioration) is 
related rather to the lens than the cornea. The visual and glare 
testing for both the better and worse eyes can give the results 
in the reference task for computer works and prognosticate 
impairments which signiﬁ  cantly affect driving performance 
for any of the driving tasks (eg, the effects of cataracts, bin-
ocular visual ﬁ  eld restriction, monocular vision).
We evaluated NAC 1% eye drops in the short-term 
9-month therapy of cataracts and for improvement of visual 
functions in older subjects with no cataract. The NAC 1% 
eyedrops seem to improve the vision of the older adult 
subjects regardless of whether they have cataracts or not, 
but the improvement of visual acuity was signiﬁ  cantly bet-
ter in the group of cataract subjects versus the older adult 
subjects in the noncataract matched older adult group. 
This is an additional mode of evidence suggesting that 
carnosine applied in the form of NAC reverses lens opac-
ity in humans [5,10, 16–18, 21–23]. Utilizing the speciﬁ  c 
purity NAC ingredient manufactured at the cGMP facility 
according to speciﬁ  cation developed by IVP (Table 1), 
as a source of pharmacological principal L-carnosine, we 
have created the ophthalmic sustained drug delivery for-
mulation (Figure 3), which contains varying amounts of 
the actives tailoring the enhanced intraocular absorption 
of the beneﬁ  cial ingredient, naturally occurring dipeptide 
L-carnosine, to optimize its specific effect and purpose in 
producing the basic bioactivating antioxidant activity in 
vivo and reducing toxic effects of lipid peroxides to the 
crystalline lens. When cataract was accompanied with 
POAG, NAC was prescribed 15 min prior the topical 
application of beta-blocker, speciﬁ  cally used to decrease 
Table 8 Mean ± SD of changes (improvement) in visual functions
Treatment group  Visual acuity  Glare radius
9-month follow-up of older subjects with cataract
Control group 0.90 ± 0.03 (n = 36) 1.53 ± 0.07 (n = 36)
NAC-treated group 1.54 ± 0.05*+ (n = 39) 0.41± 0.05* (n = 39)
9-month follow-up of older adult noncataract subjects
Control group 0.96 ± 0.03 (n = 35) 1.27 ± 0.05 (n = 35)
NAC-treated group 1.20 ± 0.04* (n = 37) 0.38 ± 0.05* (n = 37)
Notes: The measure of visual acuity readings after 9 months of treatment was divided 
by the clinical baseline measure of visual acuity for each eye individually to get ratios, 
and then the average of those ratios through each clinical group of eyes was calculated. 
Similarly with glare, the calculating of the ratio of glare sensitivity at red and green 
target after 9 months of treatment to the baseline reading of glare sensitivity for each 
eye was undertaken, and then the ratios were averaged through the whole groups 
of eyes. *p  0.001 compared to control group who received placebo eye drops; 
+p  0.001, where an improvement of visual acuity is statistically signiﬁ  cantly better 
in the group of older subjects with cataract than an improvement of visual acuity in 
the group of older adult noncataract subjects.
Abbreviation: NAC, N-acetylcarnosine (Can-C™).Clinical Interventions in Aging 2009:4 45
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Table 9 Can-C™ testimonials
“I’d like to thank you for researching and developing Can-C™. During an eye exam, they informed me I had the start of cataracts and would likely need 
surgery in about 5 yrs. I was 56 and horriﬁ  ed, especially as I am the designated driver for my social unit: me, mom and our diabetic friend who’s legally-
blind from retinopathy.
I searched the net and learned about Can-C™. Calling around to double-check their safety, I was shocked to learn that there was no NIH or other 
government studies. One researcher I talked to said that as long as there was an effective treatment- meaning surgery, there would be little chance of 
any studies being done, at least he was honest about the entrenched nature/power of the cataract surgery crowd.
Anyway, I started the drops 2-drops each eye twice a day, within 3 weeks; there was a signiﬁ  cant and dramatic improvement which continued for 
awhile longer. Now I use 1-drop in each eye daily; 2-drops if I indulge in lots of carbohydrates. Plus the Can-C™ drops are especially soothing when my 
eyes are tired and gritty feeling.”
L. P. California
“Good news to report! It is too good for words. I have been using the Can-C™ eye drops for a month for cataracts in both eyes. First thing I noticed 
was that lights seem brighter and have noticed that print is easier to read. I am near-sighted also, so being able to see numbers more clearly on a hymn 
board across the room is very exciting! I am hoping for more clarity as I continue to use the drops. This is too good to be true but it really is.”
C. K. Ireland
“I used Can-C™ for 4-months with amazing results. My vision in my left eye improved from 20/40 to 20/25 and upon renewal of my driving license, the 
eye glass restriction was eliminated! With less glare and near perfect vision I now drive in the evenings and early morning without glasses, much as I did 
in my youth 30-years ago! Since birth, my right eye could only identify the big “E” on the eye chart. After 4-months of Can-C™ treatment, I can now read 
the 3rd line on the eye chart. It’s truly amazing to be nearly blind in my right eye for 60 years and now regain some sight!” 
Dr R. L. Hawaii
“For several years I have suffered from uveitis and macula edema in one eye. The macula edema has settled but the uveitis is only controlled with corti-
costeroid eye drops. I tried to gradually reduce the corticosteroid drops and replace them with the carnosine, but this was not entirely successful and 
after a visit to the specialist I am back using the coticosteroid drops. I didn’t know whether it would be of any value to use both at the same time. What 
the carnosine did do was reduce the pressure and as both my parents had glaucoma I am very conscious of the need to keep the pressure down. So I 
may need to use the carnosine for that in the future and of course I realize that extended use of the steroid drops can cause cataracts.”
J. K. Australia
“Most of my patients are using Can-C™ as prevention; but some started it as a cure for the beginning of their cataracts. Keep up the good work.”
Dr D.K. New York
I have used your Can-C™ drops for 3 or 4 months and have noticed clearer vision. I stopped using the drops and my vision became fuzzy again. So I 
restarted the drops about two weeks ago. I will continue to use them and plan to reorder when necessary. The results were good, but know that I need 
to use them on an ongoing basis.”
E.K. Utah
“I have used Can-C™ eye-drops at a rate of approximately 2 drops /day in each eye for 3-months. I was suffering from brunescent cataracts and unrec-
ognized night blindness in both eyes, I can report these results in that time.”
1.   My night vision has returned, and I again feel safe driving at night. The halo around bright lights is very much diminished; some small “sparkles” remain, 
but do not present any problem for me.
2.  I have found no negative side-effects.
3.  My vision has improved by approximately “2 chart lines” and I can again read highway signs without glasses.
R.L. Colorado
I have been using Can-C™ for about three months now and have noticed an improvement in my vision. Also I am not waking in the mornings with 
gummed up and watery eyes as was the case previously. I should know more after my next eye examination.”
J.E. Australia
“I have purchased Can-C™ for my mother who has senile cataracts. Anecdotal reporting from her after a few months is that she feels she can see better.”
J.H., Colorado
“My ophthalmic physician wants to know what I have been doing! He hasn’t seen anything like it before in 20 years of assisting people with cataracts!”
K. L. New York
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Table 9 (Continued)
“Congratulations, these eye drops are the real McCoy, they’re great!”
G. K. Washington
“I took some eye drops for 4 months that did nothing. I’ve only been taking Can-C™ eye drops for 4-weeks and can already see the difference”.
A. M. Canada
“I can’t express the delight I feel at having to avoid surgery, your eye drops have given great hope for the future.”
M. J. K. Colorado
“I just wanted you to know that the improvement in my vision is amazing. I had gotten to the point where I could no longer drive due to haziness from 
my cataracts, and now I feel very secure and am able to see almost as well as before my cataracts were diagnosed. Also, I have not noticed any kind of 
side effects. I just wanted to tell you how happy I am and that I am deﬁ  nitely recommending Can-C™ eye-drops to all my friends with similar problems! 
If you need me for any referrals or statistics I would be happy to help! Please keep on with the great work!”
A.B. Kansas
I have been taking the Can-C™ eye-drops since February. I had my vision checked in April and my vision has improved four times and my lens is clearing. 
I get my vision checked again in July. I will keep you informed of my progress. Can-C™ drops have been a godsend to me.”
B.K. Bermuda
I want to tell you about my experiences with the special Russian eye-drops. At ﬁ  rst I didn’t think there were any real differences, but I persisted in using 
the drops twice a day in the affected eye. Now after about 3 months I believe that there are signiﬁ  cant changes to my vision. It’s been a fairly gradual 
thing which may explain why I didn’t appreciate any changes early on, but now it’s obvious to me that my eyesight has improved. The changes are slower 
than I anticipated, but I for one am sold on the drops!”
C.B.S. Hong Kong
“I have received 4 boxes of Can-C™ and only used them for 4 days as I write this at one drop/day in the left eye, my “problem” eye. I felt immediate relief 
the very ﬁ  rst day of using the drops, it was uncanny. Then I thought, maybe it was all mental, that I wanted them to work for me. So at the fourth day it is 
difﬁ  cult to tell you how much better the eye feels now. I was having extreme sensitivity to sunlight in the left eye, now it hardly bothers me. The eye had 
been feeling “swollen” and it was difﬁ  cult for me to look upward, I had to lower my head back to look up at anything. All this appears to be disappear-
ing. Before I started with the Can-C™, I went to see an ophthalmologist. I was given a complete examination for cataracts, macular degeneration and 
glaucoma, and he saw a slight beginning of a cataract and macular degeneration, the glaucoma was not mentioned. This doctor did absolutely nothing for 
the actual problem I went in for, simply told me to use a warm, moist compress on that left eye for 15 minutes, twice a day, but it did no good. I worked 
all my years as a research biochemist for a leading pharmaceutical company, so I am familiar with the medical terms and do know that the acetyl radical 
does take the carnosine through the membranes. I am very excited about these drops, thank you so much for these drops, you cannot imagine how 
much my well being has changed since using them, my left eye problem had simply consumed me completely, I found myself snapping and being rude to 
my closest of friends all because of that most uncomfortable eye problem. Thanks so much.”
R. S. Alabama
“I started using the Can-C™ eye drops and found that it started to clear the cataract but stopped. I chose a cheaper brand that was not approved by 
IVP. This actually has made the cataract worse! Then I read Dr. Babizhayev’s statement about the dangers from the imitators- which I have shown to be 
the case. I shall be back to the Can-C™ as soon as possible.”
P.S. Dubai
“I’ve been using Can-C™ for a month and I’ve noticed an improvement in my vision, particularly less glare, I intend to keep using it and let you know 
the results.”
P.M.J. Australia
“The Can-C™ eye-drops have given improvement to my mother’s eyesight over the past 3 weeks. It is certainly amazing.”
J.C. Texas
“Can-C™ eye-drops may be one of the most signiﬁ  cant advances and developments for aging eyes, especially as they appear to be able to substitute for 
surgery in many cases.”
P.M. Great Britain
“Can-C™ represents a real breakthrough and a genuine example of antiaging medicine at its best.”
Dr R.M. Switzerland
(Continued)Clinical Interventions in Aging 2009:4 47
N-Acetylcarnosine lubricant eye drops to control signs of glare sensitivity and cataract amelioration
Table 9 (Continued)
“As a medical doctor, at ﬁ  rst I was dubious of such a breakthrough, but I assisted my mother-in-law with the application; the results have been so impres-
sive I am now contacting you with a view to a wholesale enquiry.”
Dr D.S. California
“Wundervoll! I write to tell you that I have many positive results with your Can-C™ drops.”
M.D. Germany
“The more regularly I use the eye-drops the more beneﬁ  t I perceive. I think Can-C™ is a real breakthrough for ageing eyes, hopefully they and the 
information about them will become popular soon; you deserve success with this great product.”
A.P.M. Great Britain
“I would like to relay to you my great satisfaction with the Can-C™ cataract drops! I have been administrating the product for approximately 2 ½ months 
to my 5-year-old Yorkshire terrier who has diabetic induced cataracts. The cataracts were completely opaque and she had no sight in either eye. The left 
eye is already partially clear of cataract and the right shows signs of clearing. Partial vision has returned. I was considering eye surgery when she was 
ﬁ  rst diagnosed, but with the results I have seen so far I feel it’s not warranted. I would highly recommend this product to anyone! Again, thank you for 
this life saver!”
L..C. New Jersey
the intraocular pressure.23 The improvement of visual 
functions in patients with cataracts associated with POAG 
was accompanied with signiﬁ  cant decrease of intraocular 
pressure and increase in the outﬂ  ow facility in the eyes of 
patients with POAG treated with the indicated combined 
therapy.23 The treatment with NAC is improving eyesight 
in older adult cataract-free patients as intraocular released 
carnosine reacts with oxygen radicals, lipid peroxidation 
products, and carbohydrate oxidation products accumulated 
in the crystalline human lens with aging.3,5
The entire body of supporting research on NAC and 
its bioactivated principle carnosine reveals its promise as 
a water-soluble universal antioxidant that works at several 
levels to defend against the oxidative stresses to the lens, 
glycosylation problems, and protect the lens proteins and the 
membrane lipids from oxidative damages thus preventing and 
reversing age-related cataracts in human eyes. Carnosine has 
been proposed to act as antioxidant in vivo and its activity 
in the crystalline lens can be related to the prevention of the 
free-radical-induced inactivation of activity of the propri-
etary antioxidant enzymes in the crystalline lens, such as 
Cu, Zn-superoxide dismutase (SOD). The protective effects 
of carnosine and related compounds against the oxidative 
damage of human SOD by peroxyl radicals generated from 
2,2’-azobis(2-amidinopropane) dihydrochloride (AAPH) 
were established.32 Carnosine exhibits an ability to inhibit 
lipid peroxidation (LPO) catalysts besides inhibiting free 
metals, scavenging OH⋅ and lipid peroxyl (RO2⋅) radicals 
or donating hydrogen ions. In addition to inhibiting the gen-
eration of lipid peroxyl radicals, carnosine catabolyzes lipid 
hydroperoxides to their alcohols both in aqueous medium 
and in a phospholipid system.2 A possibility exists from our 
studies that carnosine is reacting directly with MDA and 
other aldehydes/ketones. Indeed carnosine has been shown to 
protect against MDA-induced crosslinking and toxicity, and 
a hydroxynonenal-carnosine adduct has recently been charac-
terized, providing further evidence for carnosine’s potential 
as an aldehyde scavenger.33 The ability of L-carnosine to 
inhibit LPO reactions as well as to diminish the content of 
LPO products makes its ophthalmic prodrug NAC applied 
with lubricant carboxymethylcellulose a prominent tool in the 
therapy especially, of the posterior subcapsular and cortical 
cataracts, whose mechanism can be related with the toxic 
effects of LPO products.34
In the cataractous lens, crosslinking of proteins by 
any means increases their effective molecular weight and 
produces light scattering and consequent lenticular opacity. 
The production of such high molecular weight protein com-
plexes by disulphide bridges and covalent links with dial-
dehydes has been implicated in the formation of senile and 
other cataracts in humans . Both types of cross-linking may 
be caused by depletion of the lens’ reduced glutathione and 
accumulation of LPO products in the lens tissue. The results 
of our studies strongly suggest that L-carnosine released 
from its ophthalmic prodrug NAC during its application to 
the eyes with cataracts is able to prevent the loss of reduced 
glutathione and to remove the secondary LPO products in 
biological systems. This, in turn, may lead to dissociation 
of the intermolecular protein cross-links due to glutathione-
protein thiol-disulphide exchange mechanism and utilization Clinical Interventions in Aging 2009:4 48
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Figure 5 Home health care service. The doctors are often committed to improving 
a vision healthcare and quality of life of a patient by providing access to the 
N-acetylcarnosine lubricant eye drops (Can-C™). To ensure the perfect plan of care, 
the distributor of eye drops will communicate frequently with the primary physician 
and with family members if a patient so desires. For insurance coverage, a doctor will 
write an order for home health nursing.
of lipid peroxides and dialdehydes derived from LPO process, 
anchoring protein-lipid complexes in the lens.35 There is a 
rising evidence that carnosine prevents oxidation and glyca-
tion, both of which contribute to the crosslinking of proteins.36 
The results suggest that histidine is the representative struc-
ture of L-carnosine for an anticrosslinking agent, containing 
the necessary functional groups for optimal protection against 
crosslinking agents. It has been proposed that the imidazo-
lium group of histidine of carnosine may stabilize adducts 
formed at the primary amino group.36 Cellular aging is often 
associated with an increase in protein carbonyl groups aris-
ing from oxidation and glycation-related phenomena and 
suppressed proteasome activity. These “aged” polypeptides 
may either be degraded by 20S proteasomes or cross-link to 
form structures intractable to proteolysis and inhibitory to 
proteasome activity. For example, effects of L-carnosine on 
proteasome activity in the lens might explain the apparent 
decline in cataract, as proteasome activity is known to decline 
during lenticular ageing.37,38
Protein glycation, which promotes aggregation, involves 
the unwanted reaction of carbohydrate oxidation products 
with proteins. Glycation of lens α-crystallin occurs in vivo and 
may contribute to cataractogenesis. Antiglycation compounds 
such as carnosine may be preventive, but interestingly car-
nosine reverses lens opacity in human trials. The mechanism 
for this observation may involve carnosine’s ability to disag-
gregate glycated protein. Seidler and colleagues39 recently 
investigated this hypothesis using glycated α-crystallin as the 
in vitro model. The obtained in the present study data can be 
satisfactorily explained by the cited above ability of carno-
sine to protect cellular and tissue structures from aldehydes, 
which in excess may be toxic because of the nonenzymatic 
glycosylation of proteins. Glycation, preferentially modiﬁ  es 
the ε-amino group of lysine residues in proteins, especially 
when proline neighbors lysine. It is likely that the structural 
similarity between lysyl-proline and β-alanyl-histidine allows 
carnosine to demonstrate its transglycation properties, eg to 
compete for the glycating agent, protecting proteins (lens 
crystallins) against modiﬁ  cation.40 This cited core action of 
carnosine may totally protect lens tissue and cellular proteins 
from aldehydes, and this effect may be the main mechanism 
by which carnosine protects the crystalline lens against 
osmotic shock, oxidative stress, or toxic effects of several 
metabolites, including the eventual crosslinking of crystalline 
lens biomacromolecules with sugar(s)’ metabolites and/or 
ascorbic acid oxidation byproducts . Actually, carnosine may 
prevent accumulation of Amadori products (forming after re-
arrangements of products of primary glycation) within lens 
cells and tissues as well as cross-linking of biomolecules.40 
At moderately high concentrations, carnosine also reverses 
protein-aldehyde cross-linking, a reaction that is difﬁ  cult to 
reverse, thus providing a rejuvenating effect on the lens for 
vision. Aggregation of crystallins, the lens proteins, is one 
of the basic stages of cataract formation. Among the protein 
aggregation models used to study the molecular mechanisms 
of the initial stages of lenticular opacity, UV-induced aggrega-
tion of βL-crystallin is most close to the in vivo conditions. 
Both carnosine and the carnosine derivative NAC have been 
shown to be effective in inhibiting the UV-induced aggrega-
tion of βL-crystallin at 20 mM concentration. The molecular 
chaperon-like properties similar to those of α-crystallin 
underlie the anticataract mechanism of action of carnosine 
and of the acetyl derivative of carnosine (prodrug).5
Carnosine when present at surprisingly high levels (about 
20 mM or over) can delay senescence of cells and reverse the 
senescent phenotype, restoring a more juvenile appearance. 
As better antioxidants/ free-radical scavengers than carnosine Clinical Interventions in Aging 2009:4 49
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impairment in the temporal cross-sections of an older popula-
tion several years apart. This ophthalmic drug showed poten-
tial for the nonsurgical treatment of age-related cataracts 
for participants after controlling for age, gender and daily 
activities and on a combined basis of repurchases behavior 
reports in various signiﬁ  cant cohort survivors, now has been 
demonstrated to have a high efﬁ  cacy and good tolerability for 
prevention and treatment of visual impairment determined 
for the older population with relative stable pattern of causes 
for blindness and visual impairment.
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